Shots: Merck KGaA to receive upfront, milestones, and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors, M9831 (formerly known as VX-984) and a preclinical candidate for six genetic disease indications to fields of gene-editing Vertex will have an option to add indications to the above […]Read More
Tags : DNA-PK Inhibitors
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US